Oncocyte Appoints Andrea James as Chief Financial Officer
17 Juin 2024 - 10:05PM
Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics
company, today announced that it has appointed leading finance
executive, Andrea James, to the position of Chief Financial
Officer.
“We are thrilled to welcome Andrea as we
approach the inflection point of commercial launch,” Oncocyte CEO
Josh Riggs said. “She has a proven track record of guiding
financial strategy through multiple phases of growth, raising and
stewarding capital, and building relationships with high quality
institutional investors. Andrea is therefore an ideal CFO business
partner to myself, the Board of Directors and the Oncocyte
team.
“We expect 2024 and 2025 to be transformative
years for Oncocyte. We have begun to establish our diagnostic tests
as the research tool of choice for the transplant community
together with our co-marketing partner Bio-Rad Laboratories.
Separately, we also see the opportunity to unlock high-value
clinical diagnostic opportunities in the oncology space and add to
our commercialization partnerships. We eagerly anticipate Andrea’s
valuable insights as we continue to drive value creation for
Oncocyte’s shareholders.”
Prior to joining Oncocyte, Ms. James served as
Chief Communications Officer and head of investor relations at Axon
Enterprise, Inc. (Nasdaq: AXON). She joined Axon’s finance team in
2017 to build the company’s investor relations function and played
an integral role through the company’s growth from $1 billion in
market capitalization to a company valued at more than $20 billion.
She led Axon’s repositioning as a top-tier technology company with
the investment community and established Axon's corporate strategy
function, overseeing capital stewardship, mergers and acquisitions,
strategic partnerships and investments. Her work was instrumental
in supporting more than $550 million in equity capital
offerings.
Ms. James worked in a strategic investor
relations role for Tesla, Inc. in 2016 and 2017. From 2009 to 2016
she worked as a sell-side analyst for Dougherty & Company (now
Colliers Securities), becoming a vice president and senior research
analyst. At Dougherty, she researched emerging technologies on
behalf of institutional investors. Previously, she was a reporter
at publications including Bloomberg News and the Seattle
Post-Intelligencer covering a range of business and financial
beats.
“Oncocyte is a disruptive innovator in the field
of molecular diagnostics that is on track for category leadership.
The company enjoys a top-notch management team with extensive
experience in this space,” Ms. James said. “I am delighted to join
and look forward to helping to scale the company into a much
larger, highly profitable enterprise over time, while also ensuring
that the capital markets understand our exciting runway and global
market opportunity.”
“I also want to commend James Liu, who has
served as Oncocyte’s controller and principal accounting officer
and who will continue to serve as an important leader within our
finance team,” James added.
Ms. James holds a Bachelor of Science, summa cum
laude, in Computer Information Systems from American University.
She also holds a Master of Science in Journalism from Northwestern
University, graduating with Kappa Tau Alpha honors. While at
Dougherty, her Financial Industry Regulatory Authority (FINRA)
licenses included the Series 7, 86, 87 and 63.
About Oncocyte
Oncocyte is a precision diagnostics company. The
Company’s tests are designed to help provide clarity and confidence
to physicians and their patients. VitaGraft™ is a clinical
blood-based solid organ transplantation monitoring test.
GraftAssure™ is a research use only (RUO) blood-based solid organ
transplantation monitoring test. DetermaIO™ is a gene expression
test that assesses the tumor microenvironment to predict response
to immunotherapies. DetermaCNI™ is a blood-based monitoring tool
for monitoring therapeutic efficacy in cancer patients. For more
information about Oncocyte, please
visit https://oncocyte.com/. For more information about our
products, please visit the following web pages:
VitaGraft Kidney™
- https://oncocyte.com/vitagraft-kidney/ VitaGraft Liver™
- https://oncocyte.com/vitagraft-liver/ GraftAssure™
- https://oncocyte.com/graftassure/ DetermaIO™
- https://oncocyte.com/determa-io/ DetermaCNI™
- https://oncocyte.com/determa-cni/
VitaGraft™, GraftAssure™, DetermaIO™, and
DetermaCNI™ are trademarks of Oncocyte Corporation.
Forward-Looking Statements
Any statements that are not historical fact
(including, but not limited to statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” “may,” and similar expressions) are forward-looking
statements. These statements include those pertaining to, among
other things, Oncocyte’s ongoing commercialization efforts and Ms.
James’ expected contributions to the Company, and other statements
about the future expectations, beliefs, goals, plans, or prospects
expressed by management. Forward-looking statements involve risks
and uncertainties, including, without limitation, risks inherent in
the development and/or commercialization of diagnostic tests or
products, uncertainty in the results of clinical trials or
regulatory approvals, the capacity of Oncocyte’s third-party
supplied blood sample analytic system to provide consistent and
precise analytic results on a commercial scale, potential
interruptions to supply chains, the need and ability to obtain
future capital, maintenance of intellectual property rights in all
applicable jurisdictions, obligations to third parties with respect
to licensed or acquired technology and products, the need to obtain
third party reimbursement for patients’ use of any diagnostic tests
Oncocyte or its subsidiaries commercialize in applicable
jurisdictions, and risks inherent in strategic transactions such as
the potential failure to realize anticipated benefits, legal,
regulatory or political changes in the applicable jurisdictions,
accounting and quality controls, potential greater than estimated
allocations of resources to develop and commercialize technologies,
or potential failure to maintain any laboratory accreditation or
certification. Actual results may differ materially from the
results anticipated in these forward-looking statements and
accordingly such statements should be evaluated together with the
many uncertainties that affect the business of Oncocyte,
particularly those mentioned in the “Risk Factors” and other
cautionary statements found in Oncocyte’s Securities and Exchange
Commission (SEC) filings, which are available from the SEC’s
website. You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date on
which they were made. Oncocyte undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made, except as required by
law.
CONTACT:
Jeff RamsonPCG Advisory(646) 863-6893jramson@pcgadvisory.com
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024